Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: A new tool in Alzheimer's disease research

Neuroscientist

Volumn 13, Issue 1, 2007, Pages 38-48

  Jack Jr , Clifford R ^a   Marjanska, Malgorzata ^b   Wengenack, Thomas M ^a   Reyes, Denise A ^a   Curran, Geoffrey L ^a   Lin, Joseph ^b   Preboske, Gregory M ^a   Poduslo, Joseph F ^a   Garwood, Michael ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

1H magnetic resonance spectroscopy; Alzheimer's disease; Alzheimer's disease therapy; Magnetic resonance microimaging; Transgenic Alzheimer's mice

Indexed keywords

ALZHEIMER DISEASE; BRAIN REGION; DISEASE COURSE; IMMUNOTHERAPY; MAGNETIC FIELD; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; RADIOISOTOPES; SENILE PLAQUES;

EID: 33845995054     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858406295610     Document Type: Review

References (66)

1. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, and others. 2003. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 5: 404 - 417.
2. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, and others. 2003. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 100: 12462 - 12467.
3. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, and others. 2002. Non-Fc-Mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 22: 7873 - 7878.
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, and others. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916 - 919.
5. Beneviste H, Einstein G, Kim KR, Hulette C, Johnson GA. 1999. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA 96: 14079 - 14084.
6. Braak H, Braak E. 1991. Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol 82: 239 - 259.
7. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. 2004. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012: 60 - 65.
8. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. 2001. Peripheral anti-A beta antibody alters CNS and plasma Aβ clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98: 8850 - 8855.
9. Dhenain M, Privat N, Duyckaerts C, Jacobs RE. 2002. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed 15: 197 - 203.
10. Dodard J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, and others. 2002. Immunization reverses memory deficits without reducing brain A-beta burden in Alzheimer's disease model. Nat Neurosci 5: 452 - 457.
11. Evans DA, Funkenstein HH, Albert MS. 1989. Prevalence of Alzheimer's disease in a community population of older persons. JAMA 262: 2551 - 2556.
12. Fagan AM, Minun MA, Mach RH, Lee SY, Dence CS, Shah AR, and others. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A-β42 in humans. Ann Neurol 59: 512 - 519.
13. Falangola MF, Lee SP, Nixon RA, Duff KE, Helpern JA. 2005. Histological co-localization of iron in A-β plaques of PS/APP transgenic mice. Neurochem Res 30: 201 - 205.
14. Ferrer I, Boada RM, Sanchez GML, Rey MJ, Costa-Jussa F. 2004. Neuropathology and pathogenesis of encephalitis following amyloidbeta immunization in Alzheimer's disease. Brain Pathol 14: 11 - 20.
15. Fukuchi KI, Accavitti-Loper MA, Kim HD, Tahara K, Cao Y, Lewis TL, and others. 2006. Amelioration of amyloid load by anti-Aβ single-chain antibody in Alzheimer mouse model. Biochemistry and Biophysics E-publication.
16. Garwood M, DelaBarre L. 2001. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J Magn Reson 153: 155 - 177.
17. Garwood M, Ke Y. 1991. Symmetric pulses to induce arbitrary flip angles with compensation for RF inhomogeneity and resonance offsets. J Magn Reson 94: 511 - 525.
18. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353 - 356.
19. Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. 2005. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. Neurobiol Aging 25: 6213 - 6220.
20. Helpern JA, Lee S-P, Falangola MF, Dyakin V, Bogart A, Ardekani B, and others. 2004. MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med 51: 794 - 798.
21. Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido T. 2005. 19F and 1H MRI detection of amyloid Beta plaques in vivo. Nat Neurosci 8: 527 - 533.
22. Holcomb L, Gordon M, McGowan E, Yu X, Benkovic S, Jantzen P, and others. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97 - 100.
23. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin D, and others. 1996. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 274: 99 - 102.
24. Jack CR Jr, Garwood M, Wengenack TM, Borowski B, Curan GL, Lin J, and others. 2004. In vivo visualization of Alzheimer's amyloid plaques by MRI in transgenic mice without a contrast agent. Magn Reson Med 52: 1263 - 1271.
25. Jack CR Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, and others. 2005. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 25: 10041 - 10048.
26. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, and others. 2000. A-beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408: 979 - 982.
27. Kantarci K, Reynolds G, Petersen R, Boeve BF, Knopman DS, Edland SD, and others. 2003. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5T and 3T. AJNR Am J Neuroradiol 24: 843 - 849.
28. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, and others. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55: 306 - 319.
29. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, and others. 2005. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598 - 10606.
30. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, and others. 2003. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23: 2086 - 2092.
31. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin LH, Hyman BT, and others. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22: 6331 - 6335.
32. Kung M-P, Hou C, Zhuang A-P, Skovronsky DM, Kung HF. 2004. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 1025: 98 - 105.
33. Kung M-P, Zhuang Z-P, Hou C, Jin L-W, Kung HF. 2003. Characterization of radioiodinated ligand binding to amyloid beta plaques. J Mol Neurosci 20: 249 - 251.
34. Lee S-P, Falangola MF, Nixon RA, Duff K, Helpern JA. 2004. Visualization of amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med 52: 538 - 544.
35. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, and others. 2006. Anti-Abeta42-and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116: 193 - 201.
36. Ma Q-L, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, and others. 2006. Antibodies against β-amyloid reduce Aβ oligomers, glycogen synthase kinase-3β activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83: 374 - 384.
37. Marjanska M, Curran GL, Wengenach TM, Henry P-G, Bliss RL, Poduslo JF, and others. 2005. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 102: 11906 - 11910.
38. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. 1993. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187: 433 - 437.
39. Moats RA, Ernst T, Shonk TK, Ross BD. 1994. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 32: 110 - 115.
40. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, and others. 2000. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982 - 985.
41. Ono M, Wilson AA, Nobrega J, Westaway D, Verhoeff P, Zhuang Z-P, and others. 2003. 11C-labeled stilbene derivative as A-beta aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 30: 565 - 571.
42. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, and others. 2002. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11: 315 - 329.
43. Ross BD, Blum S, Cowan R. 1998. In vivo MR spectroscopy of human dementia. Neuroimaging Clin North Am 8: 809 - 822.
44. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, and others. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173 - 177.
45. Schuff N, Amend DL, Ezekiel F, Steinman SK, Tanabe J, Norman D, and others. 1997. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology 49: 1513 - 1521.
46. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, and others. 2002. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58: 928 - 935.
47. Selkoe DJ. 1995. Deciphering Alzheimer's disease: molecular genetics and cell biology yield major clues. J NIH Res 7: 57 - 64.
48. Selkoe DJ. 1998. Molecular pathology of Alzheimer's disease: the role of amyloid. In: The dementias: blue book of neurology series. Newton, MA: Butterworth-Heinemann. p 257 - 283.
49. Shoghi-Jadid K, Barrio JR, Kepe V, Wu HM, Phelps ME, Huang SC. 2005. Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 32: 337 - 351.
50. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, and others. 2002. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Psychiatry 10: 24 - 35.
51. Shonk T, Ross BD. 1995. Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med 33: 858 - 861.
52. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, and others. 1995. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195: 65 - 72.
53. Silver MS, Jospeh RI, Hoult DI. 1984. Highly selective TT/2 and TT pulse generation. J Magn Reson 59: 347 - 351.
54. Skovronsky DM, Zhang B, Kung M-P, Kung HF, Trojanowski JQ, Lee VM. 2000. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97: 7609 - 7614.
55. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, and others. 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572 - 580.
56. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A. 2005. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med 53: 607 - 613.
57. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, and others. 2004. In-vivo imaging of Alzheimer disease beta-amyloid with (11C)SB-13 PET. Am J Geriatr Psychiatry 12: 584 - 595.
58. von Kienlin M, Kunnecke B, Metzger F, Steiner G, Richards JG, Ozmen L, and others. 2005. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18: 32 - 39.
59. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, and others. 2003. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Mag Reson Med 50: 293 - 302.
60. Wengenack TM, Curran GL, Poduslo JF. 2000a. Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 18: 868 - 872.
61. Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF. 2000b. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101: 939 - 944.
62. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, and others. 2006. Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26: 5340 - 5346.
63. Wilcock DM, Munireddy SK, Rosenthal A, Ugen K, Gordon MN, Morgan D. 2004a. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol Dis 15: 11 - 20.
64. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, and others. 2004b. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144 - 6151.
65. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, and others. 2004c. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24-24.
66. Zhang J, Yarowsky P, Gordon MN, DiCarlo G, Munireddy S, van Zijl PCM, and others. 2004. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Mag Reson Med 51: 452 - 457.